miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma

Lei Yu; Xuejun Gong; Lei Sun; Hong Yao; Baoling Lu; Liying Zhu

doi:10.18632/oncotarget.4407

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma

Lei Yu, Xuejun Gong, Lei Sun, Hong Yao, Baoling Lu and Liying Zhu _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2015; 6:39225-39234. https://doi.org/10.18632/oncotarget.4407

Metrics: PDF 1633 views | HTML 2265 views | ?

Abstract

Lei Yu1,*, Xuejun Gong2,*, Lei Sun3, Hong Yao1, Baoling Lu1, Liying Zhu1

1Department of Infectious Disease, The Fourth Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China

2Department of Biliary and Pancreatic Surgery, Xiangya Hospital of Central South University, Changsha, 410008, Hunan, China

3Department of Ophthalmology, The Fourth Hospital of Harbin Medical University, Harbin 150001, Heilongjiang, China

*These authors contributed equally to this work

Correspondence to:

Li-Ying Zhu, e-mail: [email protected]

Lei Yu, e-mail: [email protected]

Keywords: hepatocellular carcinoma, microRNA, miR-454, CHD5

Received: May 11, 2015 Accepted: July 17, 2015 Published: July 30, 2015

ABSTRACT

Previous studies showed that miR-454 acted as an oncogene or tumor suppressor in cancer. However, its function in HCC remains unknown. In this study, we found that miR-454 expression was upregulated in HCC cell lines and tissues. Knockdown of miR-454 inhibited HCC cell proliferation and invasion and epithelial mesenchymal transition (EMT), whereas overexpression of miR-454 promoted HCC cell proliferation and invasion and EMT. Furthermore, we identified the CHD5 as a direct target of miR-454. CHD5 was downregulated in HCC tissues and cell lines and the expression level of CHD5 was inversely correlated with the expression of miR-454 in HCC tissues. In addition, knockdown of miR-454 inhibited the growth of HepG2-engrafted tumors in vivo. Taken together, these results indicated that miR-454 functioned as an oncogene in HCC.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 4407

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

miR-454 functions as an oncogene by inhibiting CHD5 in hepatocellular carcinoma

Abstract